期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 276, 期 1-2, 页码 150-158出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2014.09.013
关键词
Autoimmune diseases; Immunotherapy; Immunoadsorption; Extracellular domains; Myasthenia gravis; MuSK antibodies
Antibodies against MuSK seem to be the pathogenic factor in approximately 5-8% of myasthenia gravis (MG) patients. We aim to develop an antigen-specific therapy in which only MuSK antibodies will be removed from patients' plasma using MuSK extracellular domain (MuSK-ECD) as immunoadsorbent We showed that two different immunoadsorbents, very efficiently and selectively depleted the MuSK antibodies from all tested sera, were stable during the procedure and were reusable. Furthermore, animal experiments showed that the treatment has no toxic effects to the animals. We conclude that the MuSK-ECD-mediated immunoadsorption can be used as an efficient antigen-specific therapy for MuSK-MG. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据